(Reuters) -AbbVie said on Monday it would launch its ovarian cancer drug Elahere in the UK at a list price equal to that in the U.S. The company was one of the 17 drugmakers to receive letters from U.S. President Donald Trump in July outlining how they should cut prices to match those paid overseas. The drugmaker said on Monday it was in discussions with Britain's cost-effectiveness watchdog National Institute for Health and Care Excellence to ensure the drug is valued fairly. Elahere belongs to a new class of treatments called antibody-drug conjugates, also called "guided missile" drugs, that precisely target cancer cells, potentially reducing toxicity for other cells. (Reporting by Mariam Sunny in Bengaluru; Editing by Leroy Leo and Sriraj Kalluvila)
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
